Ignite Creation Date:
2025-12-25 @ 3:47 AM
Ignite Modification Date:
2026-03-21 @ 11:10 PM
Study NCT ID:
NCT04633902
Status:
UNKNOWN
Last Update Posted:
2022-12-06
First Post:
2020-11-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
Sponsor:
California Pacific Medical Center Research Institute
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CPMC19-MEL01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | OTHER | View |